Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 7980
TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227484(US9334271, 5)
Affinity DataIC50: 21nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227510(US9334271, 31)
Affinity DataIC50: 28nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227494(US9334271, 15)
Affinity DataIC50: 60nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227485(US9334271, 6)
Affinity DataIC50: 66nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227505(US9334271, 26)
Affinity DataIC50: 67nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227493(US9334271, 14)
Affinity DataIC50: 76nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227502(US9334271, 23)
Affinity DataIC50: 78nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227497(US9334271, 18)
Affinity DataIC50: 91nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227481(US9334271, 2)
Affinity DataIC50: 104nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227496(US9334271, 17)
Affinity DataIC50: 112nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227500(US9334271, 21)
Affinity DataIC50: 122nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227480(US9334271, 1)
Affinity DataIC50: 139nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227492(US9334271, 13)
Affinity DataIC50: 143nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227482(US9334271, 3)
Affinity DataIC50: 164nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227486(US9334271, 7)
Affinity DataIC50: 184nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227491(US9334271, 12)
Affinity DataIC50: 194nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227498(US9334271, 19)
Affinity DataIC50: 296nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227495(US9334271, 16)
Affinity DataIC50: 308nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227489(US9334271, 10)
Affinity DataIC50: 343nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227509(US9334271, 30)
Affinity DataIC50: 364nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227503(US9334271, 24)
Affinity DataIC50: 369nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227504(US9334271, 25)
Affinity DataIC50: 380nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227490(US9334271, 11)
Affinity DataIC50: 385nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227499(US9334271, 20)
Affinity DataIC50: 484nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227511(US9334271, 32)
Affinity DataIC50: 533nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227507(US9334271, 28)
Affinity DataIC50: 754nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227488(US9334271, 9)
Affinity DataIC50: 860nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227487(US9334271, 8)
Affinity DataIC50: 1.03E+3nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227508(US9334271, 29)
Affinity DataIC50: 1.31E+3nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227501(US9334271, 22)
Affinity DataIC50: 1.51E+3nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227483(US9334271, 4)
Affinity DataIC50: 2.12E+3nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase mTOR(Human)
Novarits

US Patent
LigandPNGBDBM227506(US9334271, 27)
Affinity DataIC50: 2.41E+3nMpH: 7.5 T: 2°CAssay Description:1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well "masterplate" and 50 nL is transferred onto 384-well a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent